Description:
Bio-Bridge Science, Inc. (Bio-Bridge) is a biotech company focused on the commercial development of biological products for the prevention and treatment of human diseases and manufacturing and sales of materials in producing vaccines. It focuses on developing and obtaining regulatory approval for commercial sale of vaccines, such as a human immunodeficiency virus (HIV) vaccine (HIV-PV Vaccine I), a vaccine designed to prevent and treat infection by the HIV, an HPV vaccine, a colon cancer therapeutic vaccine and other related potential products. Bio-Bridge produces and sells bovine serum, a major production material in producing vaccines, through its 51% owned subsidiary, Bio-Bridge XHBD. The Company has finished the pre-clinical animal testing of HIV-PV Vaccine I through collaboration with Beijing Institute of Radiation Medicine. The Company’s colon cancer vaccine is a Papillomavirus Pseudovirus containing a plasmid encoding carcinoembryonic antigen (CEA) that is to be given orally.

Officers and Directors:
Liang Qiao M.D. Chairman of the Board, Chief Executive Officer, Secretary
Age: 49
Wenhui Qiao President, Director
Age: 40
Chuen Huei Lee Chief Financial Officer
Age: 39
Toshihiro Komoike Vice President, Director
Age: 57
Isao Arimoto Vice President, Director
Age: 61
Shyh-Jing Chiang Director
Age: 49
Trevor Roy Director
Age: 63
Hin Shun Cheung Director

Contact:
1211 West 22nd Street, Suite 615
Oak Brook, IL 60523
United States - Map
+1-630-9280869 (Phone)
+1-630-2036088 (Fax)